Additional therapy improves outcomes in completely resected, limited-stage follicular lymphoma

Therese Y. Andraos, Zeina Ayoub, Loretta J. Nastoupil, Sarah A. Milgrom, Chelsea C. Pinnix, Sweet Ping Ng, Jillian R. Gunther, Nathan H. Fowler, Sattva S. Neelapu, Felipe Samaniego, Luis E. Fayad, Bouthaina S. Dabaja

Research output: Contribution to journalArticlepeer-review

1 Scopus citations

Abstract

Patients with early-stage nodal follicular lymphoma (FL) may be rendered free of detectable disease by a diagnostic excisional biopsy. We reviewed the management and outcomes of 48 patients with FL, diagnosed from 2003–2013, treated at a single institution. The primary endpoints were local control (LC) and progression-free survival (PFS). Median age at diagnosis was 54.5 years (range 15–74 years). Forty-seven patients were stage I (97.9%); 15 patients (31.3%) had grade 3 disease. Initial management consisted of observation (12 patients; 25.0%), radiation therapy (RT) alone (12 patients; 25.0%), systemic therapy alone (9 cases; 18.8%), or both (15 patients; 31.3%). Median follow-up was 4.92 years (range 0.5–13.83 years). 4-year PFS and OS were 80.9% and 97.1%, respectively. Patients treated with additional therapy experienced significantly better 4-year LC (100% vs. 81.8%; p =.012) and 4-year PFS (86.7% vs. 63.6%; p =.006). Patients with completely resected limited-stage FL would benefit from therapy beyond excisional biopsy alone.

Original languageEnglish (US)
Pages (from-to)3258-3265
Number of pages8
JournalLeukemia and Lymphoma
Volume60
Issue number13
DOIs
StatePublished - Nov 10 2019

Keywords

  • Early-stage follicular lymphoma
  • completely resected nodal follicular lymphoma
  • excisional biopsy
  • nodal follicular lymphoma
  • radiation therapy

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Additional therapy improves outcomes in completely resected, limited-stage follicular lymphoma'. Together they form a unique fingerprint.

Cite this